Nitric oxide-generating beta-adrenergic blocker nipradilol preserves postischemic cardiac function

BACKGROUND

Preconditioning protects the heart from ischemic injury, but some of its effects are reversed by beta-adrenergic blockade. We hypothesize that because nitric oxide is known to precondition the heart, the nitric oxide-generating beta-blocker nipradilol may simultaneously precondition and provide clinically relevant beta-blockade.

METHODS

Isolated, crystalloid-perfused rabbit hearts underwent 1 hour of left anterior descending coronary artery ischemia followed by 1 hour of reperfusion. Before ischemia, six hearts received nipradilol, six received the nitric oxide donor L-arginine, four hearts received the nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester before L-arginine, nine underwent ischemic preconditioning, and six received beta-blockade by esmolol before ischemic preconditioning. Seven hearts received no pretreatment (control). Action potential duration and ventricular pressure were measured. Infarct size was determined at the end of reperfusion.

RESULTS

Both L-arginine and ischemic preconditioning prolonged action potential duration significantly at 60 minutes of reperfusion. Compared with control, infarct size was reduced by ischemic preconditioning (26%+/-4% versus 49%+/-3%, IPC versus control; p<0.01), L-arginine (24%+/-2%; p<0.01 versus control), and nipradilol (24%+/-2%; p<0.01 versus control). Only nipradilol preserved peak developed pressure during reperfusion.

CONCLUSIONS

Despite its properties as a beta-adrenergic blocking agent, nipradilol was able to precondition the heart, probably as a result of its ability to produce nitric oxide.

Adenosine-enhanced ischemic preconditioning decreases infarct in the regional ischemic sheep heart

BACKGROUND

Recently we have reported a myoprotective protocol, adenosine-enhanced ischemic preconditioning, that extends the protection afforded by ischemic preconditioning in the isolated crystalloid-perfused heart. In this report the efficacy of adenosine-enhanced ischemic preconditioning in the in situ blood-perfused heart was investigated.

METHODS

Sheep were subjected to 60 minutes of regional ischemia and 120 minutes of reperfusion. Ischemic preconditioned hearts received 5 minutes of zero flow regional ischemia and 5 minutes of reperfusion before regional ischemia. Adenosine-enhanced ischemic preconditioned hearts received a bolus injection of 10 mmol adenosine at the immediate start of ischemic preconditioning. Adenosine-treated hearts received an adenosine bolus, 10 minutes before regional ischemia. The ratio of infarct size to area at risk and mechanical function were determined.

RESULTS

The infarct size to area at risk ratio in regional ischemia was 55.4%+/-2.1%. This ratio was significantly decreased with ischemic preconditioning and adenosine (22.2%+/-2.2% and 19.3%+/-1.4%, respectively; p < 0.001 versus regional ischemia) and adenosine-enhanced ischemic preconditioning (8.0%+/-2.0%, p < 0.001 versus regional ischemia and ischemic preconditioning, and p < 0.01 versus adenosine).

CONCLUSIONS

Adenosine-enhanced ischemic preconditioning significantly decreases infarct size in the in situ blood-perfused heart and provides superior protection compared with ischemic preconditioning.

Phorbol-12,13-dibutyrate and pinacidil cardioplegia. Novel forms of myoprotection

BACKGROUND

Activation of either protein kinase C or the ATP-sensitive potassium channel has been shown to induce the preconditioning response.

METHODS AND RESULTS

To investigate whether preconditioning activation adjuvant to hypothermic blood cardioplegia enhances postischemic contractile recovery, 23 adult (0.5 to 1.0 year old) sheep were randomized to receive cardioplegia based on the hyperpolarizing ATP-sensitive potassium channel opener pinacidil, the protein kinase C activator 4 beta-phorbol-12, 13-dibutyrate (PDBu), or standard potassium-magnesium (K1/Mg2+). All groups underwent 60 minutes of 10 degrees C antegrade intermittent blood cardioplegia and 30 minutes of reperfusion. Mechanics were assessed on modified right heart bypass by the preload recruitable stroke work relation and the end-systolic pressure-volume relation. Diastolic function was modeled by the exponential time constant of isovolumic left ventricular pressure decay (Tau) and the "stiffness" coefficient (beta) of the end-diastolic pressure volume relation. Recovery rhythm was defined by the first electrical activity seen during reperfusion. Cardioplegic arrest and preconditioning induced by pinacidil provided superior recovery of contractile function compared with PDBu (100% versus 57% recovery, P < .05) or K+/Mg+ (100% versus 56% recovery, P < .05). Active (Tau) and passive (beta) diastolic function was preserved by all three arrest modalities. Hearts treated with pinacidil demonstrated a rapid recovery of a coordinated contraction pattern, which was offset by a reperfusion tachycardia, whereas PDBu arrest was associated with ventricular fibrillation on reperfusion.

CONCLUSIONS

Preconditioning during cardioplegic arrest is agent specific, feasible at cold temperatures, and may be superior to the use of standard K+/Mg2+ cardioplegia.

Is the preconditioning response conserved in senescent myocardium?

BACKGROUND

Senescent myocardium differs from adult myocardium at both functional and cellular levels. To adjudicate the efficacy of ischemic preconditioning as an alternative or adjuvant myoprotective strategy a reproducible, age-independent, intact laboratory model is necessary.

METHODS

Adult (0.5 to 1.0 years) and senescent (5.7 to 8.0 years) sheep underwent 60 minutes of normothermic regional ischemia with 150 minutes of reperfusion. Group II (adult-ischemic preconditioning) and group IV (aged-ischemic preconditioning) underwent preconditioning with three 5-minute episodes of normothermic regional ischemia. Group I (adult-control) and group III (aged-control) were not preconditioned.

RESULTS

Risk size and infarct size weights were delineated by monastryl blue pigment infusion and buffered tetrazolium solution. Ischemic preconditioning was evidenced by an infarct size reduction of 54% for adult sheep and 47% for senescent sheep (p < 0.01 versus age-matched controls; p = not significant for adult versus senescent).

CONCLUSIONS

The data suggest that the cellular pathways involved with the preconditioning response are well preserved in senescent myocardium and support the utility of the ovine heart model to investigate the clinical relevance of ischemic preconditioning for the increasingly aged population presently undergoing cardiac operations.

Does cardiopulmonary bypass alone elicit myoprotective preconditioning?

BACKGROUND

Brief episodes of ischemia can precondition myocardium. Ischemic preconditioning (PC) has been proposed as an adjuvant method of improving myocardial protection during cardiac surgery. It is unknown whether CPB without an episode of ischemia generates the PC response.

METHODS AND RESULTS

To prove that PC occurs in sheep, groups 1 (non-CPB control) and 2 (non-CPB ischemic PC, three 5-minute episodes of normothermic regional ischemia) were studied. Groups 3 (CPB alone), 4 (CPB-alpha receptor blockade, phentolamine 5 mg/kg), and 5 (CPB-adenosine receptor blockade, 8-sulfophenyltheophylline 5 mg/kg) were placed on CPB for 30 minutes and subsequently weaned. All groups underwent 60 minutes of normothermic regional ischemia and 150 minutes of reperfusion. The area at risk (AR) was delineated by Monastryl blue pigment, whereas the infarct size (IS) was determine by tetrazolium staining. Body mass, left ventricular mass, and AR were not different between groups. Ischemic PC was demonstrated in this ovine model by a 54% reduction of IS relative to AR (group 1 versus group 2, P < .01). CPB alone produced a similar percentage IS reduction without ischemia (group 3 versus group 1, P < .01) that was prevented by either alpha-adrenergic receptor (group 4 versus group 3, P < .01) or adenosine receptor (group 5 versus group 3, P < .01) blockade.

CONCLUSIONS

CPB alone appears sufficient to elicit the PC response important for myocardial protection during cardiac surgery. These data suggest that myocardial alpha-adrenergic receptor and adenosine receptor stimulation are involve in initiating CPB-induced PC.

Does aprotinin increase the myocardial damage in the setting of ischemia and preconditioning?

BACKGROUND

Aprotinin reduces postoperative bleeding in cardiac operations, but its association with perioperative myocardial infarction remains controversial. Ischemic preconditioning is a novel method of myocardial protection.

METHODS

To answer whether aprotinin increases postischemic myocardial damage and also to characterize the effect of aprotinin on ischemic preconditioning, four groups of sheep were fully heparinized to keep activated clotting time readings greater than 750 seconds and subjected to 60 minutes of normothermic regional ischemia (diagonal artery occlusion) with 3 hours of reperfusion. Group I was the control with no treatment, group II received aprotinin (1 million KIU load followed by 250,000 KIU/h), group III underwent ischemic preconditioning (three 5-minute intervals of ischemia and reperfusion) before prolonged 1-hour ischemia, and group IV underwent similar ischemic preconditioning and received aprotinin. Area at risk was delineated by monastryl blue pigment, and infarction size by tetrazolium staining.

RESULTS

The ratios of weight of area at risk to left ventricular weight and left ventricular weight to body weight were constant between groups. Infarction size to area at risk ratio data demonstrated that aprotinin increases infarction size by 60% (infarction size to area at risk ratio from 52% +/- 10% to 84% +/- 10% for I versus II; p < 0.001). Aprotinin also attenuates the protective effect of ischemic preconditioning (infarction size to area at risk ratio from 25% +/- 4% to 41% +/- 6%; p < 0.001).

CONCLUSIONS

In the setting of ischemia, aprotinin increases myocardial damage. If, however, the heart is provided with protective preconditioning, then the deleterious effect of aprotinin may be neutralized. From these data we suggest that aprotinin should not be used routinely in cardiac operations unless extensive blood loss is anticipated, such as in redo open heart operations.

Blood cardioplegia in the senescent heart

As an increasingly aged population undergoes cardiac surgery, myocardial protective strategies must address the fundamental differences between adult and senescent myocardium. In a test of the hypothesis that senescent myocardium is less tolerant of cardioplegic arrest, adult (0.5 to 1.0 years) and senescent (6 to 9 years) sheep underwent 55 minutes of hypothermic blood cardioplegic arrest. A 5-minute dose of terminal warm blood cardioplegic solution was administered followed by 30 minutes of vented reperfusion. Left ventricular volume was monitored by means of sonomicrometric crystals in three orthogonal planes. Myocardial function was assessed with the preload recruitable stroke work relationship. Diastolic function was assessed with two techniques: the "stiffness" coefficient (beta), derived from the exponential end-diastolic pressure-volume relationship, and the time constant of isovolumic left ventricular pressure decay (tau). Data were acquired before arrest and after the reperfusion period. Contractility in the adult hearts was well preserved (preload recruitable stroke work: 63.7 +/- 6.1 versus 56.8 +/- 4.1 mJ/beat per milliliter per 100 gm, prearrest versus postarrest, p = not significant). In contrast, senescent heart contractility was poorly preserved (56.8 +/- 4.1 versus 35.4 +/- 4.2 mJ/beat per milliliter per 100 gm, p < 0.025). Early diastolic relaxation (tau) was prolonged in the adult hearts (42.5 +/- 3.3 versus 48.8 +/- 3.5 msec prearrest versus postarrest, p < 0.05), whereas the senescent hearts were essentially unchanged (49.3 +/- 3.1 versus 52.3 +/- 4.5 msec. p = 0.35). Myocardial stiffness (beta) was unchanged in both groups. When compared with adult hearts, contractility in senescent hearts is poorly preserved after cold blood cardioplegic arrest. Active diastolic relaxation, however, is more prolonged in adult hearts. Passive diastolic properties are unchanged in both groups. Because there are specific age-related differences in tolerance to cardioplegic arrest, extrapolation of myocardial protective strategies from studies in adult hearts to elderly patients may not be appropriate.

Ischemia-dependent efficacy of phosphodiesterase inhibition

To evaluate the inotropic efficacy of phosphodiesterase inhibition in hearts with and without ischemic injury, 27 sheep were evaluated sonomicrometrically during incremental volume loading on right heart bypass. Contractility was assessed with the preload recruitable stroke work relationship. Active relaxation rate was estimated using the time constant of isovolumic pressure decay (tau). For nonischemic assessment, groups 1 and 2 (n = 6 each) underwent 45 minutes of vented perfusion after which milrinone was administered to group 1; group 2 served as nonischemic controls. There was no detectable increase in preload recruitable stroke work or decrement in tau after milrinone administration. Groups 3 and 4 underwent 15 minutes of 37 degrees C ischemia (aortic cross-clamping) followed by 30 minutes of vented reperfusion. Milrinone was then administered to group 3 (n = 7); group 4 (n = 8) served as ischemically injured controls. Inotropic and lusitropic effects were present (group 3 preload recruitable stroke work: 35.4 +/- 5.8 mJ.beat-1.100 g-1.mL-1 before milrinone to 49.5 +/- 4.4 mJ.beat-1.100 g-1.mL-1 after milrinone [p < 0.05]; group 3 tau: 51.8 +/- 5.5 ms before milrinone to 32.2 +/- 2.5 ms after milrinone [p < 0.02]). Although milrinone restored contractility and increased the rate of active relaxation in the postischemic hearts, there was no detectable inotropic effect in nonischemic hearts. In this model, milrinone augments contractility and relaxation in postischemic myocardium but offers little inotropic benefit in non-ischemically injured hearts.